Zafirlukast

Excerpt

Zafirlukast belongs to the leukotriene receptor antagonist (LTRA) class of medications and is utilized for managing and treating chronic asthma. The medication is available in 10 mg and 20 mg chewable tablets approved by the U.S. Food and Drug Administration (FDA) for use in adults and children 5 or older. Zafirlukast is also used as an off-label medication to manage chronic urticaria, prevent exercise-induced bronchospasm, and treat allergic rhinitis. As per the Global Initiative for Asthma (GINA) guidelines, LTRA, including montelukast or zafirlukast, is an essential controller therapy for patients who cannot tolerate inhaled corticosteroids (ICS). This activity reviews the mechanism of action, adverse event profile, indications, effects, contraindications, and other crucial factors relevant to utilizing zafirlukast as an agent in managing and prophylaxis of chronic asthma.